Adam Bellack

Adam Bellack is an industry-focused transactional lawyer in Goodwin’s Life Sciences group. He handles joint ventures, licenses, collaborations and other strategic, commercial and intellectual property transactions for clients engaged in all aspects of the healthcare industry. Adam’s clients range from startups and early stage pharma, biotech and medical device companies, to established Big Pharma companies and global manufacturers. Adam has also represented founders, venture funds, universities, hospitals, health systems and tech companies entering the healthcare space. Adam has worked on large transformative transactions and transactions involving cutting-edge technologies at the forefront of medical innovation, including novel immunotherapies, antibody-drug conjugates, drug delivery systems and gene therapies. His experience representing industry participants on “all sides” of these transactions provides unique perspective and helps him identify practical solutions to difficult problems when structuring and negotiating complex arrangements for life sciences companies.

Adam advises clients on a broad range of transactional matters, including strategic transactions, commercial arrangements and research agreements.

Adam’s experience includes representing:

• Representing OncoC4 in its strategic collaboration with BioNTech to co-develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody for $200 million upfront plus milestones and double-digit tiered royalties
• Seagen in connection with licensing, collaboration and commercial agreements including:
  
  • its collaboration and license agreement with Nurix for $60 million upfront and up to $3.4 billion in milestones to develop “degrader-antibody conjugates,” a new class of cancer drugs
  • its collaboration and license agreement with Sanofi to develop and commercialize multiple antibody-drug conjugates
  • its global co-commercialization agreement with Genmab for TIVDAK™ (tisotumab vedotin-tftv)
  • its collaboration and license agreement with Zai Lab to develop and commercialize TIVDAK™ (tisotumab vedotin-tftv) in greater China
  • its global co-commercialization agreement with Astellas for PADCEV™ (enfortumab vedotin-ejfv)*
• Moderna in cross-border distribution agreements for its COVID-19 vaccine
• Flagship Pioneering and Pioneering Medicines in licensing transactions and strategic collaborations
• Tessera Therapeutics in connection with licensing transactions, strategic collaborations, and commercial agreements including its collaboration agreement with Serotiny to engineer and optimize programmable Gene Writer proteins
• BridgeBio in its exclusive license agreement with Bristol Myers Squibb to develop and commercialize BBP-398 in oncology for an upfront payment of $90 million, up to $815 million in additional milestone payments and royalties
• Q32 Bio in its collaboration and option agreement with Horizon Therapeutics to research, develop and commercialize ADX-914 for the treatment of autoimmune diseases for up to $55 million in near-term payments and $645 million in closing and milestone payments
• Aura Biosciences in connection with licensing, commercial and research agreements
• OncoC4 in connection with its formation, equity financings, licensing transactions, and commercial agreements
• OncoImmune in its sale to Merck for an upfront payment of $425 million plus milestones and additional payments, and in its spinout of OncoC4 and AcroImmune
• Gilead Sciences and Kite Pharma in parallel collaboration and license agreements with oNKo-innate to support discovery and development of next-generation drug and engineered cell therapies using natural killer (NK) cells* 
• BeneVir Biopharm, Pansend Life Sciences and HC2 Holdings in the sale of BeneVir and its oncolytic virus platform to Janssen Biotech, a subsidiary of Johnson & Johnson, for up to $1.04 billion in upfront and milestone payments*
• Novartis in connection with:
  
  • its landmark portfolio transformation transactions with GlaxoSmithKline and Eli Lilly valued at more than $23 billion*
  • restructuring transactions and product divestitures including (i) the out-license of its selective PI3K-delta inhibitor, leniolisib, to Pharming Group, and (ii) the sale of Korean rights to Famvir (famciclovir) to Ildong Pharmaceuticals*
• Sanofi in its $2.2 billion global collaboration with Regeneron to develop new antibody-based immuno-oncology products*
• NextCure in connection with its formation, $67 million Series A financing and license and research agreements with Yale University*
• TESARO in connection with its formation, equity financings, licensing transactions, and commercial agreements, including its license and collaboration agreement with Janssen Biotech involving Niraparib for the treatment of prostate cancer*
• OncoImmune in connection with its option and license agreement with Pfizer and in other licensing and commercial agreements*
• Precigen in connection with exclusive channel collaboration agreements, joint ventures, and the restructuring of its biofuels business*
• A global technology company in licensing its glucose monitoring "smart lens" technology, and in the creation of a JV to develop next generation surgical robots*

*Denotes experience prior to joining Goodwin.

Prior to joining Goodwin, Adam was most recently a partner at Hogan Lovells US LLP in Washington, DC, where he served as co-head (Americas) of the Life Sciences Transactions team.

Adam was a 2021 recommended lawyer for Healthcare: life sciences  by The Legal 500 2021. Adam has been consistently recognized as a “Rising Star” by Law360 and as one of the nation’s top young Life Sciences lawyers. He has also been ranked by Super Lawyers for his work in mergers & acquisitions, health care, technology transactions, and business/corporate matters.